

The usage of RWE in Monitoring and Managing Health Technologies in Latin America

ISPOR Latin America: from 2017 to 2019

**Gerardo Machnicki, Claudia Soares,
Guilherme Julian, Ramiro Gilardino**

7th ISPOR Latin America meeting

Bogota, Colombia

13 September, 2019


1

Disclosure

- All the contents in this presentation do not represent my employer and do not compromise in any way its point
- All the comments and opinions expressed are personal

2

Three essential aspects to develop useful real world evidence



7th ISPOR Latin America Meeting| Machnicki

3

Wide applicability of RWE - 2017



- Safety**
- Reimbursement / HTA**
- Label expansion**
- Clinical trial recruitment**
- Quality improvement**
- “Value-Based” Healthcare**
- Treatment decisions**
- Population health**

Jon Duke, Georgia Tech Institute

7th ISPOR Latin America Meeting| Machnicki

4

Focus on macro aspects - 2019




Regulatory packages
HTA
Uncertainty management

- Safety
- Effectiveness
 - Comparative effectiveness
 - Other support to risk sharing agreements

7th ISPOR Latin America Meeting| Machnicki


5

Three essential aspects to develop useful real world evidence – A qualitative comparison - 2017



6

Three essential aspects to develop useful real world evidence – What's new since 2017?



7th ISPOR Latin America Meeting| Machnicki

7

Conclusions

- RWE is becoming more important for decision making, with international progress verified in terms of
 - Uses of RWE
 - Data platforms, with evolution of collaborative groups
- In Latin America, continuing interest and trends are verified
 - Emergent awareness of uses beyond HTA
 - Collaboration around RWE integrated platforms are relatively scarce or absent in the region and require maturity in health information platforms
 - First verifiable experiences into setting data infrastructures that will facilitate RWE use
 - ISPOR role continues to evolve and innovate:
 - RWE in plenary session
 - First RWE methods short course
 - RWE Industry Subcommittee contributions

7th ISPOR Latin America Meeting| Machnicki

8

Conclusions and workshop questions

- RWE adoption will be dictated by meaningful use
 - Regulatory, Safety, HTA, management of uncertainty
 - Centralized Health system have more visible use of RWE for HTA and management of uncertainty
 - **Which use(s) one will predominate in Latin America 2021? And where in Latin America?**
- Health systems fragmentation is no barrier to develop large scale, reusable RWD
 - Need investments (people + time) and some standards
 - Public resources are needed in different models of development
 - US FDA
 - EU Public/private partnerships
 - **By 2021, we will see significant progress in the development of robust RWD valid for macro uses (yes/no)...led by significant streams of public(yes/no) and/or private (yes/no) resources**

7th ISPOR Latin America Meeting| Machnicki

9

Thank you!

Gerardo Machnicki, MSc., PhD.

7th ISPOR Latin America meeting
Bogota, Colombia
13 September 2019

10